Ten-Year Follow-Up of a Randomized Trial of Pravastatin in Heart Transplant Patients

普伐他汀 医学 随机对照试验 心脏移植 内科学 心脏病学 移植 胆固醇
作者
Jon A. Kobashigawa,J. Moriguchi,Hillel Laks,Liane Wener,A. Hage,Michèle A. Hamilton,Gregory Cogert,A. Márquez,Maria Espejo Vassilakis,Jignesh Patel,Lawrence A. Yeatman
出处
期刊:Journal of Heart and Lung Transplantation [Elsevier BV]
卷期号:24 (11): 1736-1740 被引量:171
标识
DOI:10.1016/j.healun.2005.02.009
摘要

Background

Outcomes from this trial's first year data demonstrated significant benefit in heart transplant patients treated with pravastatin in cholesterol levels, survival, rejection with hemodynamic compromise, the development of cardiac allograft vasculopathy, and decreased natural killer cell cytotoxicity. Other heart transplant studies have shown similar benefit. We now report the 10-year follow-up of this study.

Methods

Ninety-seven heart transplant recipients were randomized to pravastatin (n = 47) or no pravastatin (n = 50) within 2 weeks after surgery both in combination with cyclosporine and corticosteroids. Ten-year outcomes include survival, cholesterol levels, and development of cardiac allograft vasculopathy documented by coronary angiography.

Results

Forty-two percent of the control patients crossed over to pravastatin treatment during the second year of the study, and 81% of the control patients were eventually placed on statin therapy by the 10-year follow-up. The control group had subsequent low and comparable cholesterol levels in Years 2 to10 of the study compared with the patients originally randomized to pravastatin. Intent-to-treat analysis demonstrated that the pravastatin group compared with control had increased 10-year survival (68% vs 48%, p = 0.026). The 10-year freedom from angiographic cardiac allograft vasculopathy and/or death in the pravastatin group was significantly greater compared with the control group (43% vs 20%, p = 0.009).

Conclusion

The 10-year follow-up of this study suggests that the use of pravastatin in heart transplant patients maintains survival benefit and appears to reduce the development of cardiac allograft vasculopathy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
桐桐应助快乐小夏采纳,获得10
刚刚
Bystander完成签到 ,获得积分10
1秒前
冰糖完成签到,获得积分20
2秒前
彭于晏应助优美霸采纳,获得10
2秒前
烟花应助奋斗雁山采纳,获得10
3秒前
好好学习完成签到,获得积分10
4秒前
5秒前
5秒前
抹茶肥肠完成签到,获得积分10
7秒前
脑洞疼应助11采纳,获得10
7秒前
7秒前
9秒前
sheila完成签到,获得积分10
9秒前
9秒前
枫叶的虫子完成签到,获得积分10
10秒前
10秒前
Pooh发布了新的文献求助10
11秒前
11秒前
12秒前
深情安青应助莫非采纳,获得10
13秒前
向阳而生o完成签到,获得积分10
13秒前
xxx发布了新的文献求助10
13秒前
14秒前
llll发布了新的文献求助10
15秒前
yao发布了新的文献求助30
15秒前
16秒前
loski发布了新的文献求助10
16秒前
可爱的函函应助偷乐采纳,获得10
18秒前
清晾油完成签到,获得积分10
18秒前
19秒前
脑洞疼应助科研通管家采纳,获得10
19秒前
科目三应助科研通管家采纳,获得10
19秒前
坦率的匪应助科研通管家采纳,获得10
19秒前
科研通AI5应助科研通管家采纳,获得10
19秒前
JamesPei应助科研通管家采纳,获得10
19秒前
解语花应助科研通管家采纳,获得50
19秒前
czh应助科研通管家采纳,获得10
19秒前
JamesPei应助科研通管家采纳,获得10
19秒前
科研通AI2S应助科研通管家采纳,获得10
19秒前
bkagyin应助科研通管家采纳,获得10
19秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988838
求助须知:如何正确求助?哪些是违规求助? 3531250
关于积分的说明 11252914
捐赠科研通 3269838
什么是DOI,文献DOI怎么找? 1804820
邀请新用户注册赠送积分活动 881943
科研通“疑难数据库(出版商)”最低求助积分说明 809028